Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: "Michael Lotze" Clear advanced filters

  • Although there are numerous immune mechanisms that destroy cancer precursors, the selection of tumour cells that are poorly immunogenic and that can subvert the immune response is crucial to the development of cancer. How these processes are linked is discussed in this Review.

    • Laurence Zitvogel
    • Antoine Tesniere
    • Guido Kroemer
    Reviews
    Nature Reviews Immunology
    Volume: 6, P: 715-727

  • Complexities in sample handling, instrument setup and data analysis are barriers to the effective use of flow cytometry to monitor immunological parameters in clinical trials. The novel use of a central laboratory may help mitigate these issues.

    • Holden T Maecker
    • J Philip McCoy Jr
    • Jung-Hua Yeh
    Comments & Opinion
    Nature Immunology
    Volume: 11, P: 975-978

  • How should the immune system respond to a dying cell? Should it ignore it (to allow normal tissue turnover), tolerate it (to prevent autoimmunity) or respond to it (to clear pathogens or tumours)? This Review describes our current understanding of the mechanisms involved in this decision.

    • Douglas R. Green
    • Thomas Ferguson
    • Guido Kroemer
    Reviews
    Nature Reviews Immunology
    Volume: 9, P: 353-363

  • Here, the authors describe how the antitumour effects of many conventional cancer treatments involve the immune system, by promoting immunogenic tumour-cell death or by direct stimulation of immune cells. Taking advantage of this 'bystander effect' may help in the fight against cancer.

    • Laurence Zitvogel
    • Lionel Apetoh
    • Guido Kroemer
    Reviews
    Nature Reviews Immunology
    Volume: 8, P: 59-73

  • A crucial role of the immune system in cancer progression and response to therapy has recently emerged. Here, Galluzzi and colleagues discuss the immune parameters that may predict the therapeutic response of patients to chemotherapeutics, and review the mechanisms by which current antineoplastic agents activate the immune system against cancer.

    • Lorenzo Galluzzi
    • Laura Senovilla
    • Guido Kroemer
    Reviews
    Nature Reviews Drug Discovery
    Volume: 11, P: 215-233

  • In this Review, Zitvogel and colleagues discuss the impact of immune parameters on the efficacy of chemotherapeutic regimens. They suggest that immune-relevant biomarkers may guide personalized therapeutic interventions including compensatory measures to restore or improve anticancer immune responses.

    • Laurence Zitvogel
    • Oliver Kepp
    • Guido Kroemer
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 8, P: 151-160

  • Type I interferons (IFNs) are best known for their role in antiviral immunity. As discussed in this Review, recent evidence indicates that these cytokines also have an integral role in natural and therapy-induced anticancer immunity. Harnessing the antineoplastic properties of type I IFNs may lead to the development of ever-more effective anticancer therapies.

    • Laurence Zitvogel
    • Lorenzo Galluzzi
    • Guido Kroemer
    Reviews
    Nature Reviews Immunology
    Volume: 15, P: 405-414